Cellectis ROCE
¿Qué es el ROCE de Cellectis?
El ROCE de Cellectis es -53.69%
¿Cuál es la definición de ROCE?
El retorno sobre el capital empleado (ROCE) es una relación financiera que mide la rentabilidad de una empresa y la eficiencia con la que se utiliza su capital.
Return on capital employed (ROCE) is the total amount of capital that a company has utilized in order to generate profits. It is the sum of shareholders' equity and debt liabilities. It can be simplified as total assets minus current liabilities.
ROCE is especially useful when comparing the performance of companies in capital-intensive sectors. ROCE considers debt and other liabilities as well compared to other fundamentals which only analyze profitability related to a company’s common equity. This provides a better indication of financial performance for companies with significant debt. For a company, the ROCE trend over the years is also an important indicator of performance. In general, investors tend to favor companies with stable and rising ROCE numbers over companies where ROCE is volatile and bounces around from one year to the next.
Instead of using capital employed at an arbitrary point in time, analysts and investors often calculate ROCE based on the average capital employed (ROACE), which takes the average of opening and closing capital employed for the time period.
ROCE de compañías en Sector Health Care en NASDAQ en comparadas con Cellectis
¿Qué hace Cellectis?
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Empresas con roce similar a Cellectis
- Continental Materials tiene ROCE de -53.90%
- CuriosityStream tiene ROCE de -53.88%
- Personalis Inc tiene ROCE de -53.75%
- Lexicon Pharmaceuticals Inc tiene ROCE de -53.73%
- Oncocyte tiene ROCE de -53.73%
- Berkeley Lights tiene ROCE de -53.73%
- Cellectis tiene ROCE de -53.69%
- Pacifico Minerals tiene ROCE de -53.63%
- SpringWorks Therapeutics tiene ROCE de -53.49%
- Profound Medical Corp tiene ROCE de -53.48%
- QC Copper and Gold tiene ROCE de -53.41%
- Minaurum Gold tiene ROCE de -53.40%
- Angus Ventures tiene ROCE de -53.35%